Telitacicept for PGNMID: A Single-Arm Study

Study Rationale Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a rare but aggressive renal manifestation of monoclonal gammopathy of renal significance (MGRS). Conventional immunosuppression yields limited and inconsistent responses; no therapy is approved specifically for PGNMID. Pathogenic immunoglobulins are produced by dysregulated B-cell or plasma-cell clones. Telitacicept is a novel TACI-Fc fusion protein that simultaneously neutralizes B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), thereby suppressing both B-cell maturation and plasma-cell survival. This mechanism may interrupt the production of the monoclonal immunoglobulins that drive PGNMID.

Objectives Primary: To determine the change in 24-hour urine protein excretion from baseline to Week 24 after telitacicept therapy.

Secondary: (1) Change in estimated glomerular filtration rate (eGFR); (2) change in urinary red-blood-cell count; (3) change in serum IgG, IgA, IgM, C3, and C4; (4) safety and tolerability.

Study Design Single-center, open-label, investigator-initiated, prospective single-arm trial. Ten adults with biopsy-proven PGNMID will be enrolled. After a 12-week run-in on optimized ACE inhibitor or ARB therapy (to confirm persistent proteinuria ≥1 g/day), participants will receive telitacicept 160 mg subcutaneously once weekly for 24 consecutive weeks. Post-treatment follow-up continues to Week 28.

Population Inclusion: Age ≥18 y; renal biopsy consistent with PGNMID; 24-h proteinuria ≥1 g on two occasions ≥4 weeks apart despite maximal ACEi/ARB; eGFR ≥20 mL/min/1.73 m² (CKD-EPI); willingness to use effective contraception.

Exclusion: Malignant hematologic disorders (e.g., multiple myeloma); eGFR <20 or rapidly progressive GN; systemic immunosuppression within 3 months; active infection, hepatitis B/C, HIV; pregnancy/lactation; hypersensitivity to study drug.

Schedule of Assessments Screening (Weeks -12 to 0): medical history, physical exam, renal biopsy review, laboratory tests, informed consent.

Treatment period (Weeks 0-24): study drug administered at Weeks 0, 4, 8, 12, 16, 20, and 24. Laboratory panels, urinalysis, adverse-event (AE) assessment, and drug accountability will be performed at every visit.

Follow-up visit (Week 28): safety laboratory tests and AE collection. Endpoints \& Statistical Plan Primary endpoint will be analyzed using a mixed-effect model for repeated measures (MMRM) with baseline proteinuria as covariate. Secondary continuous outcomes will be analyzed similarly. Descriptive statistics will summarize safety data. All participants who receive ≥1 dose will be included in safety analysis; modified intention-to-treat set will be used for efficacy. Missing data will be handled by multiple imputation. One-sided α = 0.05; no formal power calculation (exploratory study).

Safety Oversight An independent Data and Safety Monitoring Committee (DSMC) will review safety data every 3 months. Serious AEs will be reported to the institutional ethics committee and sponsor within 24 hours. A 24-hour emergency contact is provided to all participants.

Regulatory \& Ethical Considerations The study is conducted in accordance with the Declaration of Helsinki and China's IIT guidelines. The Biomedical Research Ethics Committee of Peking University First Hospital approved the protocol (approval number：2025R-0014). Telitacicept is used off-label; this is explicitly detailed in the informed-consent form and hospital medical-affairs record.

Data Management Electronic case-report forms are maintained on a secure, password-protected server with daily back-ups. Only authorized study personnel have access. Participant identifiers are replaced by coded study IDs.